Tempus AI expands collaboration with Gilead Sciences to maximize oncology pipeline insights

What happened: On April 9, Tempus AI (TEM) and Gilead Sciences (GILD) expanded their multi-year oncology R&D collaboration. Tempus will provide Gilead enterprise-wide access to its AI-driven Lens platform, aiming to accelerate drug discovery and development. This follows a bullish upgrade of Tempus by TD Cowen on April 13, citing expanding partnerships. Notably, Nancy Pelosi, the 47th Speaker of the U.S. House of Representatives, exercised 50 call options on Tempus AI stock in late January 2026.

Market impact: This development benefits the oncology drug development sector. Gilead, a leading biopharmaceutical company, gains access to advanced AI tools to enhance its pipeline. Tempus, a medical AI company, strengthens its position in the market, attracting investor attention. Hedge funds and analysts view both companies favorably, with Gilead among the '8 Best Quality Stocks to Buy' and Tempus among the 'best medical AI stocks to buy now'.

What to watch next: Upcoming catalysts include Tempus' Q1 2023 earnings release on May 15, which will provide insights into the financial impact of its expanding partnerships. Additionally, watch for progress updates on the Tempus-Gilead collaboration, particularly any successful drug candidates or milestones achieved using Tempus' AI platform. Lastly, monitor any regulatory decisions related to AI in healthcare, which could impact Tempus' growth trajectory.